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Background: Despite significant progresses in antimicrobial therapy, infectious diseases caused by bacteria and
fungi remain a major worldwide health problem because of the rapid development of resistance to existing
antimicrobial drugs. Therefore, there is a constant need for new antimicrobial agents. There are a large number of
heterocyclic derivatives containing nitrogen atoms that possess a broad spectrum of biological activities including
pyridine and pyridazine, which are two of the most important heterocycles in medicinal chemistry.
Results: The reaction of 3-oxo-2-arylhydrazonopropanals 2 with ethyl cyanoacetate and malononitrile 3a,b has led
to the formation of 2-amino-5-arylazo-6-aryl substituted nicotinates 8a-k as sole isolable products when the aryl
group in the arylazo moiety was substituted with an electron-withdrawing group like Cl, Br, NO2. The pyridazinones
10 were formed from the same reaction when the arylazo moiety was phenyl or phenyl substituted with an
electron-donating group. The 2-aminoazonicotinates 8 were condensed with DMF-DMA to afford the amidines 13a,
b, which then were cyclized to afford the targeted pyrido[2,3-d]pyrimidine derivatives 15a,b, respectively. The
structures of all new substances prepared in this investigation were determined by using X-ray crystallographic
analysis and spectroscopic methods. Most of the synthesized compounds were tested and evaluated as
antimicrobial agents and the results indicated that many of the obtained compounds exhibited high antimicrobial
activity comparable to ampicillin, which was used as the reference compound.
Conclusion: A general rule for the synthesis of 2-amino-5-arylazo-6-aryl substituted nicotinic acid and pyridazinone
was established using 3-oxo-2-arylhydrazonopropanal as a precursor. Moreover, a novel route to pyrido[2,3-d]
pyrimidine was achieved. Most of the synthesized compounds were found to exhibit strong inhibitory effects on
the growth of Gram-positive bacteria especially Bacillus subtilis. Compounds 1a, 8a-h, 10a-c, 15b and 16 showed a
broad spectrum of antimicrobial activity against B. subtilis.
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The emergence and spread of antimicrobial resistance
has become one of the most serious public health con-
cerns across the world. Antimicrobial resistance refers
to microorganisms that have developed the ability to in-
activate, exclude, or block the inhibitory or lethal effects
of antimicrobial agents [1]. Despite significant progress
in antimicrobial therapy, infectious diseases caused by
bacteria and fungi remain a major worldwide health
problem because of the rapid development of resistance
to the existing antimicrobial drugs (antibacterial and
antifungal). In other words, the increasing use and
misuse of existing antimicrobial drugs have resulted in
the development of resistant pathogens. In particular,
the emergence of multidrug-resistant Gram-positive
and -negative bacteria has caused life-threatening infec-
tious diseases in many countries. The chemical and
biological study of heterocyclic compounds has been of
interest for many years for medicinal and agricultural
reasons. There are a large number of heterocyclic deriva-
tives containing nitrogen atoms such as pyridine and
pyridazine that possess a broad spectrum of biological
activities including antimicrobial [2-6], anti-inflammatory
and analgesic [7-9], anti-HIV [10], antiplasmodial [11],
anti-tubercular [3,12], antibacterial [3,13], anticonvulsant
[14,15], inhibition of cyclo-oxygenase [16], antidiabetic
[17], antihypertensive [18], anticancer [19-22], inhibition
of blood platelet aggregation [23], antidepressant and
anxiolytic [24,25], antioxidant [26] and antifungal [27].
Thus, the extensive biological activities of pyridine and
pyridazine make them important in the design of drug-
like molecules. Encouraged by the afore-mentioned find-
ings and in a continuation of an ongoing program aimed
at finding new structural leads with potential potent anti-
bacterial and antifungal agents [28,29], this study describes
the synthesis of a new class of 2-amino-5-arylazo-6-aryl




The reaction of the 3-oxo-2-arylhydrazonopropanals 2
with the active methylene reagents has been investigated
in the past [30]. Recently, it was shown that this reaction
affords either arylazo-2-oxonicotinates 6 or pyridazinones
10 [31]. However, the factors that control the nature of
the end product could not be defined. In the present
article, we report the synthesis of several derivatives of 2
with electron-donating and -withdrawing substituents on
the arylazo moiety and identified the exact structure of the
products of their reaction with the active methylene re-
agents 3a,b. It could be concluded that the reaction of 3
with 2 having an electron-donating substituent on the
arylazo moiety afforded only the pyridazinones 10 whilereacting 3 with 2 having an electron-withdrawing substitu-
ent on the arylazo moiety either in the p, m, or o position
or a mix of them affords only the 2-amino-5-arylazo-6-aryl
substituted nicotinic acid derivatives 8. Thus compounds
2a-k were prepared via coupling of 1 with aromatic diazo-
nium salts [30] (cf. Scheme 1 and Figure 1). Reacting 2a-g
with ethyl cyanoacetate 3a or with malononitrile 3b af-
fords the 2-amino-5-arylazo-6-aryl substituted nicotinates
8a-k as confirmed from accurate mass determination and
elemental analyses. Moreover, the structures were also
confirmed from the X-ray single crystal structure deter-
mination for 8a, 8b, 8c, and 8h (cf. Figures 2, 3, 4, and 5,
Tables 1, 2, and Scheme 1). It is believed that initially
the acyclic condensation products 4 were formed and
then these cyclize to the pyranimine 5 that reacts with
ammonia from the reaction medium to yield the acyclic
intermediate 7 that further cyclizes into the final isolable
2-aminonicotinic acid derivatives 8. Under these condi-
tions, no traces of the arylazo-2-oxonicotinates 6 or 2-
hydroxy-5-arylazonicotinates were isolated as reported by
Al-Mousawi et al. [31,32]. On the other hand, the reaction
of 2h-k having a phenyl or a phenyl substituted with an
electron-donating group on the arylhydrazone moiety with
3a afforded the pyridazinones 10a-d. It is believed that
also in this case, the acyclic intermediate 4 was formed
and then cyclized via attack of the arylhydrazone moiety
at CN to afford the pyridazine imine intermediate 9 that
was hydrolyzed under the reaction conditions to yield the
final isolable pyridazinone 10. The structure of 10 was also
supported by both the classical analytical analyses and
through the X-ray crystal structure determination for 10a
(cf. Figure 6, Table 3, and Scheme 1). It is believed that the
basicity of the hydrazone moiety of 2 controls the nature
of the final product as it facilitates the reversible
cyclization of the intermediate 4 and at the same time
helps to stabilize the cyclized 9, thus allowing the hy-
drolysis step to proceed to form the pyridazinone 10. In
contrast, cyclization of 4 is highly reversible and a com-
peting cyclization reaction takes place resulting in
formation of the pyranimine 5, which in the presence of
ammonium ion led to the formation of the stable
aromatic 2-aminonicotinic acid derivatives 8.
The obtained arylazoaminonicotinates are interesting
precursors for the synthesis of a variety of a novel
arylazoheterocycles that may possess interesting biological
activities. Reaction of the 2-amino-5-arylazonicotinates 8
with acetic anhydride afforded the mono- and the di-
acetylated products 11 and 12, respectively, depending
upon the reaction time. The structures of the products
11a and 12 were confirmed by X-ray single crystal deter-
mination (cf. Scheme 2, Figures 7, 8).
Moreover, the 2-amino-5-arylazonicotinates 8 reacted
with dimethylformamide dimethylacetal (DMF-DMA)
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Scheme 1 Synthesis of 2-amino-5-arylazonicotinic acid 8 and pyridazinone derivatives 10.
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http://journal.chemistrycentral.com/content/7/1/12313a,b reacted with ammonia in refluxing acetic acid to
yield the corresponding pyrido[2,3-d]pyrimidine deriva-
tives 15a,b. The structures of these products were also
confirmed by different spectroscopic analyses as illus-
trated in the experimental section. Furthermore, fusion
of the azonicotinates 8f with thiourea afforded the
corresponding pyrido[2,3-d]pyrimidine derivatives 16
(cf. Scheme 3).Antimicrobial activity
The novel chemical compounds synthesized in this study
showed promising antimicrobial activities. In general,
most of the tested compounds revealed better activity
against Gram-positive rather than the Gram-negative
bacteria and yeast. The results as depicted in Table 4
show strong activities against Gram-positive bacteria be-
cause all of the tested chemicals showed highly positive
Figure 1 ORTEP plot of the X-ray crystallographic data determined for 2a and 2h.
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http://journal.chemistrycentral.com/content/7/1/123antimicrobial activities against B. subtilis with inhibition
zones >10 mm. Only the tested chemical 1a displayed
strong inhibitory effects on the growth of Escherichia coli
(Gram-negative bacteria), Bacillus subtilis, and Staphylo-
coccus aureus (Gram-positive bacteria), which showed in-
hibition zones exceeding 10 mm. It also strongly inhibited
the growth of Candida albicans (yeast) while the cyclo-
heximide did not inhibit growth of this yeast. None of the
chemicals except 1a inhibited the growth of Gram-
negative bacteria or yeast. Moreover compounds 2a, 2c,
2d, and 2g had high inhibitory activities against the Gram-
positive bacteria S. aureus. The tested chemicals 8a-h and
10a-c displayed very strong inhibitory effects toward the
growth of the Gram-positive bacteria B. subtilis with in-
hibition zones exceeding the reference chemotherapeutic
ampicillin (cf. Table 4). Compounds 8a and 10c were also
nearly as active as ampicillin against B. subtilis (MIC =
12.5 μg/mL). It was found that transformation of theFigure 2 ORTEP plot of the X-ray crystallographic data
determined for 8a.enaminones 1 into the corresponding arylhydrazonals
2 generally decreased the inhibitory effects while trans-
formation of the latter into the corresponding 2-
amino-5-arylazo-6-aryl substituted nicotinates 8 or the
pyridazinone 10 resulted in inhibition of the growth of
only B. subtilis (Gram-positive bacteria) as revealed by the
diameters of their inhibition zones. Conversely, conversion
of the 2-aminoazonicotinates derivatives into the corre-
sponding acetyl, diacetyl, or amidine derivatives exempli-
fied by compounds 11, 12, and 13 unfortunately resulted
in a decrease in the inhibitory effects but still had inhib-
ition zones >10 mm. Fusing the pyridine ring into the
bicyclic pyrido[2,3-d]pyrimidine derivatives 15a,b and 16
enhanced the antimicrobial activity because the majority
of these compounds were active against only the Gram-
positive bacteria B. subtilis and S. aureus.
 Structure activity relationship
By comparing the experimental biological activity of
the compounds reported in this study with their
structures, the following structural activity
relationship assumptions are postulated.
➢ The pyridine or pyridazine moieties are necessary
to observe the higher antibacterial activities towards
the Gram-positive bacteria B. subtilis.
➢ It is interesting to point out that for the
azonicotinates 8 having an electron-withdrawing
group in the arylazo moiety in the para-, meta-
and ortho- positions like compounds 8a-e or
having two electron-withdrawing groups in the
arylazo moiety as in 8f and 8h results in higher
antibacterial activity as evidenced by the inhibition
zones that were similar (Table 4), and from the
minimum inhibitory concentration (MIC) values
presented in Table 5. This indicates that high
antimicrobial activity may be correlated with the
low electron density of the ring systems and the role
of an electron-withdrawing group in increasing the
Figu
det
Figure 3 ORTEP plot of the X-ray crystallographic data determined for 8b.
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http://journal.chemistrycentral.com/content/7/1/123antimicrobial potency is similar to the results of
Sharma et al. [33].
➢ It is worth mentioning that changing the
COOEt group to a CN group as in 8f and 8h has
no significant effect on the biological activity.re 4 ORTEP plot of the X-ray crystallographic data
ermined for 8c.➢ The presence of a Me or OMe (electron-
donating group) in the aryl moiety in position 2 as in
the pyridazine 10b,c enhances the biological activity.
➢ Transformation of the azonicotinates 8 to the
pyrido[2,3-d]pyrimidine derivatives 15a,b and 16
does not significantly affect the biological activity
against the Gram-positive bacteria B. subtilis.Experimental
General
Melting points were recorded on a Griffin melting point
apparatus and are reported uncorrected. IR spectra were
recorded using KBr disks using a Perkin-Elmer System
2000 FT-IR spectrophotometer. 1H-NMR (400 MHz) or
(600 MHz) and 13C-NMR (100 MHz) or (150 MHz)
spectra were recorded at 25°C in CDCl3 or DMSO-d6 as
solvent with TMS as internal standard on a Bruker DPX
400 or 600 super-conducting NMR spectrometer. Chem-
ical shifts are reported in ppm. Mass spectra were mea-
sured using a high resolution GC-MS (DFS) thermo
spectrometers with EI (70 EV). Microanalyses were
performed on a LECO CHNS-932 Elemental Analyzer.
Follow up of the reactions and checking homogeneity of
the prepared compounds was made by thin layer chroma-
tography (TLC). All single crystal data collections were
made either on Rigaku R-AXIS RAPID diffractometer
using Mo-Kα radiation (for samples 8a, 8c, 8h, 11a and
12) or on Bruker X8 Prospector using Cu- Kα radiation
(for compounds 2a, 2h, 8b, and 10a). The data were
Figure 5 ORTEP plot of the X-ray crystallographic data determined for 8h.
Ibrahim et al. Chemistry Central Journal 2013, 7:123 Page 6 of 16
http://journal.chemistrycentral.com/content/7/1/123collected at room temperature. The structure was solved
by direct methods and was expanded using Fourier tech-
niques. The non-hydrogen atoms were refined anisotropi-
cally. In the case of compounds 8a, 8c, 8h, 11a and 12, all
calculations were performed using the Crystal Structure
[34] crystallographic software package except for refine-
ment, which was performed using SHELXL-97 [35]. In the
case of 2a, 2h, 8b, and 10a the structure was solved and
refined using the Bruker SHELXTL Software Package
(Structure solution program- SHELXS-97 and Refinement
program- SHELXL-97) [35] (cf. Additional files 1, 2, 3, 4,
5, 6, 7, 8, 9 and Table 6). Data were corrected for the ab-
sorption effects using the multi-scan method (SADABS).
The enaminones 1a,b and the arylhydrazonals 2a-k were
prepared according to the literature procedure [30,31].
General procedure for the preparation 2-amino-5-arylazo-6-
aryl substituted nicotinates 8a-k
Independent mixtures of 2a-g (10 mmol), active
methylenenitrile derivatives 3a,b (10 mmol), and am-
monium acetate (2 g) in acetic acid (20 mL) were stirredTable 1 Selected bond lengths and bond angles for 8a
Bond Bond length(Å) Bond Bond angle(o)
N3-C8 1.332 C8-N3-C9 119.4
N3-C9 1.363 N3-C8-C7 122.5
N4-C9 1.327 N3-C8-C12 114.5
C9-C10 1.421 N3-C9-N4 116.3
N1-C1 1.427 N4-C9-C10 122.5
N1-N2 1.259 N1-N2-C7 116.0
N2-C7 1.406 N2-C7-C8 116.1at reflux for 1–2 h. (the progress of the reactions was
monitored by using TLC using 1:1 ethyl acetate-
petroleum ether as eluent). The mixtures were cooled
and then poured into ice-water. The solids that so
formed were collected by filtration and crystallized from
the proper solvents to give 8a-k as pure products.
2-Amino-6-(4-chlorophenyl)-5-(4-chlorophenylazo) nicotinic
acid ethyl ester (8a)
Recrystallized from an EtOH/dioxane (3:1) mixture as
orange crystals, yield: (80%), m.p. 208–210°C; IR (KBr):
ν /cm−1 3409, 3278 (NH2), 1699 (CO ester);
1H-NMR
(DMSO-d6): δ = 1.35 (t, 3H, J = 7.2 Hz, CH3CH2), 4.37
(q, 2H, J = 7.2 Hz, CH3CH2), 7.57-7.63 (m, 4H, Ar-H),
7.73 (d, J = 8.4 Hz, 2H, Ar-H), 7.81 (d, J = 8.4 Hz, 2H,
Ar-H), 7.88, 8.14 (two br, 2H, NH2, D2O exchangeable)
and 8.58 ppm (s, 1H, pyridine H4); 13C-NMR (DMSO-
d6): δ = 14.19 (CH3), 61.23 (CH2), 105.42 (pyridine
C3), 124.12, 127.51, 127.71, 129.60, 132.75, 134.42,
135.02, 135.93, 136.38, 150.89, 159.79, 160.62 andTable 2 Selected bond lengths and bond angles for 8h
Bond Bond length(Å) Bond Bond angle(o)
N4-C8 1.344 C8-N4-C9 119.6
N4-C9 1.352 N4-C9-C10 120.8
N6-C9 1.342 N4-C8-C7 121.3
C9-C10 1.422 N4-C9-N6 116.9
C10-C18 1.433 N6-C9-C10 122.3
N5-C18 1.148 C9-C10-C18 119.6
N2-N3 1.254 N5-C18-C10 179.2
N3-C7 1.412 N2-N3-C7 115.2
Figure 6 ORTEP plot of the X-ray crystallographic data determined for 10a.
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http://journal.chemistrycentral.com/content/7/1/123166.13 ppm (Ar-C and CO); MS (EI): m/z (%) 414 (M+,
100), 415 (M++1, 70.85). Anal. calcd. for C20H16Cl2N4O2
(415.28): C, 57.85; H, 3.88; N, 13.49. Found: C, 57.93; H,
3.77; N, 13.57.
2-Amino-6-(4-chlorophenyl)-5-(4-nitrophenylazo)nicotinic
acid ethyl ester (8b)
Recrystallized from an EtOH/dioxane (2:1) mixture as
deep orange crystals, yield: (85%), m.p. 230–231°C; IR
(KBr): ν /cm−1 3402, 3297 (NH2), 1717 (CO ester);
1H-
NMR (DMSO-d6): δ = 1.36 (t, 3H, J = 7.2 Hz, CH3CH2),
4.36 (q, 2H, J = 7.2 Hz, CH3CH2), 7.58 (d, J = 8.4 Hz, 2H,
Ar-H), 7.80-7.86 (m, 4H, Ar-H), 7.98, 8.31 (two br, 2H,
NH2, D2O exchangeable), 8.35 (d, J = 8.4 Hz, 2H, Ar-H)
and 8.57 ppm (s, 1H, pyridine H4); 13C-NMR (DMSO-d6):
δ = 14.11 (CH3), 61.25 (CH2), 105.60 (pyridine C3),
123.24, 125.03, 127.46, 127.70, 132.76, 134.58, 135.68,
136.65, 147.58, 155.58, 160.15, 161.64 and 165.94 ppm
(Ar-C and CO); MS (EI): m/z (%) 425 (M+, 100), 426
(M++1, 57.92). Anal. calcd. for C20H16ClN5O4 (425.83):
C, 56.41; H, 3.79; N, 16.45. Found: C, 56.50; H, 3.72; N,
16.40.Table 3 Selected bond lengths and bond angles for 10a
Bond Bond length(Å) Bond Bond angle(o)
N1-N2 1.346 N1-N2-C13 126.04
N1-C6 1.312 N1-N2-C7 114.44
N2-C13 1.413 C13-N2-C7 119.32
O2-C13 1.217 N2-C13-C14 112.98
O1-C5 1.220 C6-N1-N2 117.37
N2-C7 1.442 O3-C16-C14 116.32-Amino-6-(4-chlorophenyl)-5-(3-chlorophenylazo)nicotinic
acid ethyl ester (8c)
Recrystallized from acetic acid as orange crystals, yield:
(76%), m.p. 188–190°C; IR (KBr): ν /cm−1 3400, 3275
(NH2), 1688 (CO ester);
1H-NMR (DMSO-d6): δ = 1.35
(t, 3H, J = 7.2 Hz, CH3CH2), 4.35 (q, 2H, J = 7.2 Hz,
CH3CH2), 7.52-7.57 (m, 4H, Ar-H), 7.61-7.66 (m, 2H,
Ar-H), 7.78 (d, J = 8.4 Hz, 2H, Ar-H), 7.87, 8.15 (two
br, 2H, NH2, D2O exchangeable) and 8.51 ppm (s, 1H,
pyridine H4); 13C-NMR (DMSO-d6): δ = 14.60 (CH3),
61.65 (CH2), 105.85 (pyridine C3), 121.99, 122.14, 127.90,
128.03, 130.44, 131.57, 133.20, 134.48, 134.91, 136.31,
136.66, 153.70, 160.34, 161.26 and 166.51 ppm (Ar-C
and CO); MS (EI): m/z (%) 414 (M+, 100), 415 (M++1,
67.45). Anal. calcd. for C20H16Cl2N4O2 (415.28): C, 57.85;
H, 3.88; N, 13.49. Found: C, 57.78; H, 3.94; N, 13.42.
2-Amino-5-(3-bromophenylazo)-6-(4-chlorophenyl) nicotinic
acid ethyl ester (8d)
Recrystallized from ethanol as deep yellow crystals, yield:
(73%), m.p. 180–181°C; IR (KBr): ν /cm−1 3420, 3286
(NH2), 1697 (CO ester);
1H-NMR (DMSO-d6): δ = 1.35
(t, 3H, J = 7.2 Hz, CH3CH2), 4.35 (q, 2H, J = 7.2 Hz,
CH3CH2), 7.48 (t, J = 8.0 Hz, 1H, Ar-H), 7.55 (d, J = 8.4
Hz, 2H, Ar-H), 7.64-7.70 (m, 2H, Ar-H), 7.75-7.80
(m, 3H, Ar-H), 7.88, 8.15 (two br, 2H, NH2, D2O ex-
changeable) and 8.51 ppm (s, 1H, pyridine H4); 13C-NMR
(DMSO-d6): δ = 14.19 (CH3), 61.24 (CH2), 105.45 (pyri-
dine C3), 122.19, 122.50, 124.44, 127.52, 127.63, 131.51,
132.80, 132.92, 134.49, 135.88, 136.24, 153.41, 159.93,
160.94 and 166.09 ppm (Ar-C and CO); MS (EI): m/z (%)










































Scheme 2 Synthesis of acylated azonicotinate derivatives 11 and 12.
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http://journal.chemistrycentral.com/content/7/1/123C20H16BrClN4O2 (459.73): C, 52.25; H, 3.51; N, 12.19.
Found: C, 52.33; H, 3.45; N, 12.23.2-Amino-6-(4-chlorophenyl)-5-(2-nitrophenylazo)nicotinic
acid ethyl ester (8e)
Recrystallized from an dioxane mixture as orange crystals,
yield: (88%), m.p. 221–222°C; IR (KBr): ν/cm−1 3394, 3280
(NH2), 1704 (CO ester);
1H-NMR (DMSO-d6): δ = 1.33
(t, 3H, J = 7.2 Hz, CH3CH2), 4.35 (q, 2H, J = 7.2 Hz,
CH3CH2), 7.50 (d, J = 8.0 Hz, 1H, Ar-H), 7.57 (d, J = 8.4
Hz, 2H, Ar-H), 7.67 (t, J = 8.0 Hz, 1H, Ar-H), 7.76-7.82
(m, 3H, Ar-H), 7.95, 8.31 (two br, 2H, NH2, D2O ex-
changeable), 8.05 (d, J = 8.0 Hz, 1H, Ar-H) and 8.47 ppm
(s, 1H, pyridine H4); 13C-NMR (DMSO-d6): δ = 14.07
(CH3), 61.26 (CH2), 105.69 (pyridine C3), 118.66, 124.14,
127.78, 128.04, 130.73, 132.66, 133.57, 134.58, 135.68,
136.81, 144.31, 147.05, 160.12, 161.46 and 165.90 ppm
(Ar-C and CO); MS (EI): m/z (%) 425 (M+, 17.25), 426
(M++1, 7.05). HRMS (EI): m/z calcd. for C20H16
35ClN5O4
(M+) 425.0885, found 425.0881.2-Amino-5-(2-chloro-5-nitrophenylazo)-6-(4-chlorophenyl)
nicotinic acid ethyl ester (8f)
Recryst- allized from DMF as deep orange crystals, yield:
(89%), m.p. 266–268°C; IR (KBr): ν /cm−1 3378, 3281
(NH2), 1709 (CO ester);
1H-NMR (DMSO-d6): δ = 1.35
(t, 3H, J = 7.2 Hz, CH3CH2), 4.38 (q, 2H, J = 7.2 Hz,
CH3CH2), 7.57 (d, J = 8.4 Hz, 2H, Ar-H), 7.85 (d, J = 8.4
Hz, 2H, Ar-H), 7.96-8.41 (m, 5H, 3Ar-H and NH2) and
8.63 ppm (s, 1H, pyridine H4); 13C-NMR (DMSO-d6, at
100°C): δ = 13.95 (CH3CH2), 61.24 (CH3CH2), 106.27
(pyridine C3), 112.67, 124.64, 127.54, 128.12, 131.94,
132.63, 134.75, 135.81, 137.06, 139.12, 147.22, 148.64,
160.30, 161.67 and 165.88 ppm (Ar-C and CO); MS (EI):
m/z (%) 459 (M+, 100), 460 (M++1, 71.22). Anal. calcd. for
C20H15Cl2N5O4 (460.28): C, 52.19; H, 3.28; N, 15.22.
Found: C, 52.23; H, 3.35; N, 15.19.
2-Amino-5-(4-chlorophenylazo)-6-(4-nitrophenyl)nicotinic
acid ethyl ester (8g)
Recrystallized from an EtOH/dioxane (2:1) mixture as
orange crystals, yield: (74%), m.p. 205–206°C; IR (KBr):
Figure 7 ORTEP plot of the X-ray crystallographic data
determined for 11a.
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http://journal.chemistrycentral.com/content/7/1/123ν /cm−1 3410, 3311 (NH2), 1723 (CO ester);
1H-NMR
(DMSO-d6): δ = 1.37 (t, 3H, J = 7.2 Hz, CH3CH2), 4.39
(q, 2H, J = 7.2 Hz, CH3CH2), 7.61(d, J = 8.4 Hz, 2H, Ar-H),
7.73(d, J = 8.4 Hz, 2H, Ar-H), 8.05 (d, J = 8.4 Hz, 2H,
Ar-H), 7.92, 8.20 (two br, 2H, NH2, D2O exchangeable),
8.37 (d, J = 8.4 Hz, 2H, Ar-H) and 8.62 ppm (s, 1H, pyri-
dine H4); 13C-NMR (DMSO-d6): δ = 14.62 (CH3), 61.78
(CH2), 106.68 (pyridine C3), 123.16, 124.65, 128.07,
130.04, 132.60, 135.64, 137.06, 143.94, 148.19, 151.27,
157.18, 160.23 and 166.44 ppm (Ar-C and CO); MS
(EI): m/z (%) 425 (M+, 100), 426 (M++1, 85.15). Anal.Figure 8 ORTEP plot of the X-ray crystallographic data
determined for 12.calcd. for C20H16ClN5O4 (425.83): C, 56.41; H, 3.79; N,
16.45. Found: C, 56.48; H, 3.85; N, 16.52.
2-Amino-5-(2-chloro-5-nitrophenylazo)-6-(4-chlorophenyl)
nicotinonitrile (8h)
Recrystallized from DMSO as reddish brown crystals,
yield: (77%), m.p. above 300°C; IR (KBr): ν /cm−1 3489,
3379 (NH2), 2220 (CN), 1628(C=N);
1H-NMR (DMSO-d6):
δ = 7.57 (d, J = 8.4 Hz, 2H, Ar-H), 7.81 (d, J = 8.4 Hz, 2H,
Ar-H), 7.96 (d, J = 8.8 Hz, 1H, Ar-H), 8.10 (s, 1H, Ar-H),
8.17 (br, 2H, NH2, D2O exchangeable), 8.27 (d, J = 8.8 Hz,
1H, Ar-H) and 8.36 ppm (s, 1H, pyridine H4); 13C-NMR
(DMSO-d6): δ = 90.85 (pyridine C3), 112.58, 115.83,
125.24, 127.69, 131.14, 132.13, 132.81, 134.92, 135.42,
136.15, 139.71, 146.97, 148.04, 160.51 and 161.67 ppm
(CN and Ar-C); MS (EI): m/z (%) 412 (M+, 100), 413
(M++1, 61.45). Anal. calcd. for C18H10Cl2N6O2
(413.23): C, 52.32; H, 2.44; N, 20.34. Found: C, 52.25;
H, 2.53; N, 20.40.
2-Amino-6-(4-chlorophenyl)-5-(4-chlorophenylazo)
nicotinonitrile (8i)
Recrystallized from dioxane as brown crystals, yield:
(69%), m.p. 278–280°C; IR (KBr): ν /cm−1 3441, 3338
(NH2), 2213 (CN), 1656 (C=N);
1H-NMR (DMSO-d6): δ =
7.53-7.59 (m, 4H, Ar-H), 7.79 (d, J = 8.4 Hz, 2H, Ar-H),
7.84 (d, J = 8.4 Hz, 2H, Ar-H), 8.10 (br, 2H, NH2, D2O
exchangeable) and 8.34 ppm (s, 1H, pyridine H4); MS (EI):
m/z (%) 367 (M+, 74.75), 368 (M++1, 29.50). Anal. calcd.
for C18H11Cl2N5 (368.23): C, 58.71; H, 3.01; N, 19.02.
Found: C, 58.62; H, 2.95; N, 19.11.
2-Amino-5-(3-bromophenylazo)-6-(4-chlorophenyl)
nicotinonitrile (8j)
Recrystallized from dioxane as brown crystals, yield:
(72%), m.p. above 300°C; IR (KBr): ν /cm−1 3424, 3317
(NH2), 2208(CN), 1639(C=N);
1H-NMR (DMSO-d6):
δ = 7.56-7.63 (m, 5H, Ar-H), 7.77-7.91 (m, 3H, 1 Ar-H
and NH2), 7.97 (d, J = 8.4 Hz, 2H, Ar-H) and 8.22 ppm
(s, 1H, pyridine H4); MS (EI): m/z (%) 412 (M+, 100),
413 (M++1, 31.26). Anal. calcd. for C18H11BrClN5




Recrystallized from a DMF/dioxane (1:1) mixture as
yellowish brown crystals: (70%), m.p. 275–276°C; IR
(KBr): ν /cm−1 3477, 3367 (NH2), 2222 (CN), 1635
(C=N); 1H-NMR (DMSO-d6): δ = 7.48 (d, J = 7.6 Hz,
1H, Ar-H), 7.57 (d, J = 8.0 Hz, 2H, Ar-H), 7.67 (t, J = 7.6
Hz, 1H, Ar-H), 7.77-7.79 (m, 3H, Ar-H), 8.04-8.10

























































Scheme 3 Synthesis of pyrido[2,3-d]pyrimidine derivatives 15 and 16.
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http://journal.chemistrycentral.com/content/7/1/123(s, 1H, pyridine H4); 13C-NMR (DMSO-d6): δ = 90.62
(pyridine C3), 115.89, 118.52, 124.17, 127.83, 131.02,
131.20, 132.65, 133.59, 134.79, 135.44, 136.42, 144.07,
147.18, 160.30 and 161.14 ppm (Ar-C and CN); MS (EI):
m/z (%) 478 (M+, 100), 426 (M++1, 46.55). HRMS (EI):
m/z calcd. for C18H11
35ClN6O2 (M
+) 378.0626, found
378.0627.General procedure for the preparation pyridazine
derivatives 10a-d
Independent mixtures of 2h-k (10 mmol), ethyl
cyanoacetate 3a (1.15 g, 10 mmol), and ammonium
acetate (2 g) in acetic acid (20 mL) were stirred at re-
flux for 1–2 h. (the progress of the reactions was moni-
tored by using TLC using 1:1 ethyl acetate-petroleum
ether as eluent). The mixtures were cooled and then
poured into iced water. The solids that so formed were
collected by filtration and recrystallized from the
proper solvents to give 10a-d as pure products.6-(4-Chlorobenzoyl)-3-oxo-2-phenyl-2,3-dihydropyridazine-
4-carboxylic acid ethyl ester (10a)
Recrystallized from an EtOH as yellow crystals, yield:
(75%), m.p. 140–141°C; IR (KBr): ν /cm−1 1715, 1690
(CO and CO ester); 1H-NMR (DMSO-d6): δ = 1.32 (t, 3H,
J = 7.2 Hz, CH3CH2), 4.35 (q, 2H, J = 7.2 Hz, CH3CH2),
7.46–7.55 (m, 3H, Ar-H), 7.60–7.62 (m, 4H, Ar-H), 8.04
(d, J = 8.4 Hz, 2H, Ar-H), and 8.33 ppm (s, 1H, pyridazine
H5); 13C-NMR (DMSO-d6): δ = 13.97 (CH3), 61.86 (CH2),
125.94, 128.48, 128.87, 128.95, 131.06, 131.93, 132.41,
133.75, 138.38, 141.04, 141.27, 155.92, 162.60, and 187.71
ppm (Ar-C and CO); MS (EI): m/z (%) 382 (M+, 100),
383 (M++1, 32.85). Anal. calcd. for C20H15ClN2O4
(382.81): C, 62.75; H, 3.95; N, 7.32. Found: C, 62.82; H,
3.92; N, 7.28.
6-(4-Chlorobenzoyl)-3-oxo-2-p-tolyl-2,3-dihydropyridazine-4-
carboxylic acid ethyl ester (10b)
Recrystallized from EtOH as yellow crystals, yield: (69%),
m.p. 94–95°C; IR (KBr): ν/cm−1 1753, 1687 (CO and CO
Table 4 Inhibition zone diameter (mm) of the tested chemicals that showed antimicrobial activities against the tested
microorganisms
Compound No. Inhibition zone diameter in
mm ± (standard deviation)
E. coli P. aeruginosa B. subtilis S. aureus C. albicans
1a 20 (0.04) 0 23 (0.02) 12 (0.02) 34 (0.05)
2a 0 0 12 (0.04) 14 (0.10) 0
2c 0 0 12 (0.02) 10 (0.03) 0
2d 0 0 12 (0.03) 10 (0.07) 0
2e 0 0 11 (0.07) 8 (0.07) 0
2g 0 0 16 (0.04) 11 (0.05) 0
8a 0 0 30 (0.07) 0 0
8b 0 0 28 (0.10) 0 0
8c 0 0 23 (0.02) 0 0
8d 0 0 25 (0.09) 0 0
8e 0 0 29 (0.03) 0 0
8f 0 0 27 (0.10) 0 0
8h 0 0 26 (0.10) 0 0
10a 0 0 22 (0.20) 0 0
10b 0 0 25 (0.02) 0 0
10c 0 0 29 (0.20) 0 0
11b 0 0 13 (0.06) 6 (0.06)
12 0 0 11(0.10) 4 (0.04)
13a 0 0 16 (0.05) 0 0
13b 0 0 17 (0.10) 0 0
15a 0 0 19 (0.02) 12 (0.07) 0
15b 0 0 23 (0.03) 9 (0.2) 0
16 0 0 25 (0.09) 14 (0.02) 0
DMSO (solvent) 0 0 0 0 0
a Ampicillin 23 (0.14) 17 (0.07) 21 (0.05) 26 (0.07) 0
b Cycloheximide - - - - 0
DMSO = Dimethyl sulfoxide, a Ampicillin antibacterial drug, b cycloheximide antifungal drug, – not tested.
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CH3CH2), 2.37 (s, 3H, CH3), 4.35 (q, 2H, J = 7.2 Hz,
CH3CH2), 7.33 (d, J = 8.4 Hz, 2H, Ar-H), 7.49 (d, J = 8.4
Hz, 2H, Ar-H), 7.62 (d, J = 8.4 Hz, 2H, Ar-H), 8.03 (d,
J = 8.4 Hz, 2H, Ar-H) and 8.32 ppm (s, 1H, pyridazine
H5); 13C-NMR (DMSO-d6): δ = 14.43 (CH3), 21.19
(CH3), 62.29 (CH2), 126.13, 128.91, 129.73, 131.41,
132.22, 132.85, 134.26, 138.75, 139.07, 139.10, 141.62,
156.38, 163.09 and 188.16 ppm (Ar-C and CO); MS (EI):
m/z (%) 396 (M+, 100), 397 (M++1, 34.52). Anal. calcd.
for C21H17ClN2O4 (396.83): C, 63.56; H, 4.32; N, 7.06.
Found: C, 63.63; H, 4.26; N, 7.15.
6-(4-Chlorobenzoyl)-2-(4-methoxyphenyl)-3-oxo-2,3-
dihydropyridazine-4-carboxylic acid ethyl ester (10c)
Recrystallized from EtOH as yellow crystals, yield: (72%),
m.p. 132–133°C; IR (KBr): ν/cm−1 1757, 1679 (CO and
CO ester); 1H-NMR (DMSO-d6): δ = 1.32 (t, 3H, J = 7.2
Hz, CH3CH2), 3.81 (s, 3H, OCH3), 4.35 (q, 2H, J = 7.2Hz, CH3CH2), 7.06 (d, J = 8.8 Hz, 2H, Ar-H), 7.53 (d, J =
8.8 Hz, 2H, Ar-H), 7.62 (d, J = 8.4 Hz, 2H, Ar-H), 8.03
(d, J = 8.4 Hz, 2H, Ar-H) and 8.31 ppm (s, 1H, pyridazine
H5); 13C-NMR (DMSO-d6): δ = 14.43 (CH3), 55.94 (CH3),
62.28 (CH2), 114.37, 127.63, 128.92, 131.28, 132.15, 132.86,
134.29, 134.40, 138.74, 141.51, 156.46, 159.75, 163.14 and
188.22 ppm (Ar-C and CO); MS (EI): m/z (%) 412 (M+,
100), 413 (M++1, 28.95). Anal. calcd. for C21H17ClN2O5
(412.83): C, 61.10; H, 4.15; N, 6.79. Found: C, 61.17; H,
4.21; N, 6.75.
6-(4-Chlorobenzoyl)-2-(2,3-dimethylphenyl)-3-oxo-2,3-
dihydropyridazine-4-carboxylic acid ethyl ester (10d)
Recrystallized from EtOH as pale yellow crystals, yield:
(70%), m.p. 96–97°C; IR (KBr): ν/cm−1 1746, 1692 (CO
and CO ester); 1H-NMR (DMSO-d6): δ = 1.33 (t, 3H, J =
7.2 Hz, CH3CH2), 2.00 (s, 3H, CH3), 2.31 (s, 3H, CH3),
4.35 (q, 2H, J = 7.2 Hz, CH3CH2), 7.24-7.31 (m, 3H, Ar-
H), 7.58 (d, J = 8.4 Hz, 2H, Ar-H), 7.95 (d, J = 8.4 Hz,
Table 6 The crystallographic data for the measured compounds [36]
Compound No. Crystal Data
2a Clear light orange Block, C15H10Cl2N2O2, M = 321.16, triclinic, a = 6.3570(3) Å, b = 7.2377(3) Å, c = 16.7375(7) Å, V = 720.87(5) Å
3,
α = 80.359(3)°, β = 82.469(3)°, γ = 72.360(3)°, space group: P −1, Z = 2, Dcalc = 1.480 g cm−3 , No. of reflection measured 2494,
2θmax = 66.60°, R1 = 0.042.
2h Clear light yellow Block, C15H11ClN2O2, M = 286.71, triclinic, a = 6.0147(2) Å, b = 7.3767(2) Å, c = 16.5968(4) Å, V = 672.60(3) Å
3,
α = 80.941(2)°, β = 85.3620(10)°, γ = 67.6940(10)°, space group: P −1, Z = 2, Dcalc = 1.416 g cm−3 , No. of reflection measured 2324,
2θmax = 66.74°, R1 = 0.036.
8a Yellow platelet crystal, C20H16Cl2N4O2, M = 415.28, triclinic, a = 7.796(1) Å, b = 11.004(2) Å, c = 12.229(2) Å, V = 987.0(3) Å
3,
α = 70.789(8)°, β = 89.602(7)°, γ = 85.231(7)°, space group: P-1, Z = 2, Dcalc = 1.397 g cm
−3 , No. of reflection measured 3995,
2θmax = 52.7°, R1 = 0.064.
8b Clear light orange flake, C20H16ClN5O4, M = 425.83, monoclinic, a = 27.918(4) Å, b = 6.632(8) Å, c = 24.125(3) Å,V = 4082.0(9) Å
3,
α = γ = 90.00°, β = 113.965(9)°, space group: C 1 2/c 1, Z = 8, Dcalc = 1.386 g cm−3 , No. of reflection measured 3434,
2θmax = 66.59°, R1 = 0.082.
8c Orange prism crystal, C20H16Cl2N4O2, M = 415.28, orthorhombic, a = 7.5481 (6) Å, b = 21.382(2) Å, c = 27.862(2) Å, V = 4496.8(6)
Å3, α = β = γ = 90.0°, space group: Pbca, Z = 8, Dcalc = 1.404 g cm
−3 , No. of reflection measured 3923, 2θmax = 50.0°, R1 = 0.067.
8h Yellow block crystal, C18H10Cl2N6O2, M = 413.23, triclinic, a = 8.918(1) Å, b = 10.696(1) Å, c = 13.217(2) Å, V =1132.2(2) Å
3, α =
73.044(6)°, β = 81.609(6)°, γ = 70.078(5)°, space group: P-1, Z = 2, Dcalc = 1.441 g cm−3 , No. of reflection measured 4609, 2θmax =
52.7°, R1 = 0.047.
10a Clear light colorless block, C20H15ClN2O4, M = 382.81, monoclinic, a = 9.8702(7) Å, b = 18.7297(14) Å, c = 19.4912(15) Å, V = 3600.1
(5) Å3, α = γ = 90°, β = 92.397(4)°, space group: P 1 21/c 1, Z = 8, Dcalc = 1.412 g cm
−3 , No. of reflection measured 6168, 2θmax =
66.63°, R1 = 0.049.
11 Yellow needle crystal, C22H17Cl2N5O5, M = 502.32, orthorhombic, a = 26.252(2) Å, b = 7.3051(5) Å, c = 24.022(2) Å, V = 4606.8(6) Å
3,
α = β = γ = 90°, space group: Pbcn, Z = 8, Dcalc = 1.448 g cm−3 , No. of reflection measured 4017, 2θmax = 50.0°, R1 = 0.059.
12 Yellow needle crystal, C24H19Cl2N5O6, M = 544.35, monoclinic, a = 8.027(1) Å, b = 14.586(2) Å, c = 21.531(3) Å, V = 2499.1(5) Å
3,
α = γ = 90°, β = 97.548(7)°, space group: P21/c, Z = 4, Dcalc = 1.447 g cm−3 , No. of reflection measured 5078, 2θmax = 52.7°,
R1 = 0.046.
Table 5 The MICs (μg/mL) of selected newly synthesized compounds against the tested microorganisms
Compound No. The minimum inhibitory concentration
(MIC) in μg/mL
E. coli P. aeruginosa B. subtilis S. aureus C. albicans
1a 50 - 50 - 12.5
2a - - 125 100 -
2g - - 100 - -
8a - - 12.5 - -
8b - - 25 - -
8c - - 50 - -
8d - 25 -
8e - - 25 - -
8g - - 25 - -
10a - - 50 - -
10b - - 25 - -
10c - - 12.5 - -
11b - - 100 - -
13a - - 100 - -
13b - - 100 - -
15a - - 100 - -
15b - - 50 - -
16 0 0 50 100 -
a Ampicillin 6.25 - 12.5 12.5 -
b Cycloheximide - - - - -
a Ampicillin antibacterial drug, b cycloheximide antifungal drug, – not measured.
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http://journal.chemistrycentral.com/content/7/1/1232H, Ar-H) and 8.38 ppm (s, 1H, pyridazine H5); MS
(EI): m/z (%) 410 (M+, 100), 411 (M++1, 35.14). Anal.
calcd. for C22H19ClN2O4 (410.86): C, 64.32; H, 4.66; N,
6.82. Found: C, 64.36; H, 4.73; N, 6.89.
General procedure for the preparation compounds 11a-c
and 12
Independent solutions of the azonicotinates 8a,c,f (10
mmol) in acetic anhydride (10 mL) were stirred at reflux
for 4 h. in case of compounds 11a-c and for 12 h. in
case of compound 12. Then, the reaction mixture was
allowed to cool to room temperature, the formed crude
product was collected by filtration washed with ethanol
and recrystallized from the proper solvent.
2-Acetylamino-5-(2-chloro-5-nitrophenylazo)-6-(4-
chlorophenyl)nicotinic acid ethyl ester (11a)
Recrystallized from EtOH/dioxane (2:1) mixture as red-
dish orange crystals, yield: (83%), m.p. 257–258°C; IR
(KBr): ν/cm−1 3231 (NH), 1719, 1673 (2 CO); 1H-NMR
(DMSO-d6): δ = 1.30 (t, 3H, J = 7.2 Hz, CH3CH2), 2.23
(s, 3H, COCH3), 4.29 (q, 2H, J = 7.2 Hz, CH3CH2), 7.64
(d, J = 8.4 Hz, 2H, Ar-H), 7.91 (d, J = 8.4 Hz, 2H, Ar-H),
8.06 (d, J = 8.4 Hz, 1H, Ar-H), 8.20 (s, 1H, Ar-H), 8.39
(d, J = 8.4 Hz, 1H, Ar-H), 8.43 (s, 1H, pyridine H4) and
11.22 ppm (s, 1H, NH); 13C-NMR (DMSO-d6): δ = 14.49
(CH3), 24.38 (CH3), 61.78 (CH2), 113.36, 119.16, 126.98,
128.44, 129.16, 131.98, 132.11, 132.78, 133.57, 135.32,
135.57, 141.21, 147.48, 148.45, 158.16, 165.63 and 170.34
ppm (Ar-C and CO); MS (EI): m/z (%) 501 (M+, 100),
502 (M++1, 72.45). Anal. calcd. for C22H17Cl2N5O5
(502.32): C, 52.61; H, 3.41; N, 13.94. Found: C, 52.64; H,
3.37; N, 13.88.
2-Acetylamino-6-(4-chlorophenyl)-5-(4-chlorophenylazo)
nicotinic acid ethyl ester (11b)
Recrys- tallized from EtOH/dioxane (3:1) mixture as
orange crystals, yield: (77%), m.p. 103–104°C; IR (KBr):
ν /cm−1 3278 (NH), 1721, 1685 (CO and CO ester); 1H-
NMR (DMSO-d6): δ = 1.30 (t, 3H, J = 7.2 Hz, CH3CH2),
2.21 (s, 3H, COCH3), 4.28 (q, 2H, J = 7.2 Hz, CH3CH2),
7.63 (d, J = 8.4 Hz, 2H, Ar-H), 7.69 (d, J = 8.4 Hz, 2H, Ar-
H), 7.85-7.88 (m, 4H, Ar-H), 8.40 (s, 1H, pyridine H4) and
11.10 ppm (s, 1H, NH); MS (EI): m/z (%) 456 (M+, 76.92),
457 (M++1, 67.22). Anal. calcd. for C22H18Cl2N4O3
(457.32): C, 57.78; H, 3.97; N, 12.25. Found: C, 57.86; H,
3.88; N, 12.27.
2-Acetylamino-6-(4-chlorophenyl)-5-(3-chlorophenylazo)
nicotinic acid ethyl ester (11c)
Recrystallized from EtOH/dioxane (3:1) mixture as orange
crystals, yield: (79%), m.p. 210–211°C; IR (KBr): ν /cm−1
3245 (NH), 1709, 1680(2 CO); 1H-NMR (DMSO-d6): δ =
1.30 (t, 3H, J = 7.2 Hz, CH3CH2), 2.21 (s, 3H, COCH3),4.28 (q, 2H, J = 7.2 Hz, CH3CH2), 7.62-7.66 (m, 4H, Ar-
H), 7.81-7.87 (m, 4H, Ar-H), 8.39 (s, 1H, pyridine H4)
and 11.11 ppm (s, 1H, NH); 13C-NMR (DMSO-d6): δ =
14.04 (CH3), 23.91 (CH3), 61.27 (CH2), 122.17, 124.06,
126.98, 127.98, 131.40, 132.93, 134.21, 134.86, 135.02,
136.95, 139.80, 140.70, 142.90, 150.33, 156.69, 165.26
and 169.75 ppm (Ar-C and CO); MS (EI): m/z (%)
456 (M+, 91.14), 457 (M++1, 85.08). Anal. calcd. for
C22H18Cl2N4O3 (457.32): C, 57.78; H, 3.97; N, 12.25.
Found: C, 57.69; H, 3.93; N, 12.31.5-(2-Chloro-5-nitrophenylazo)-6-(4-chlorophenyl)-2-
diacetylaminonicotinic acid ethyl ester (12)
Recrystallized from EtOH as red crystals, yield: (89%),
m.p. 229–230°C; IR (KBr): ν/cm−1 3231 (NH), 1720,
1705, 1681 (3 CO); 1H-NMR (DMSO-d6): δ = 1.31
(t, 3H, J = 7.2 Hz, CH3CH2), 2.31 (s, 6H, 2COCH3),
4.36 (q, 2H, J = 7.2 Hz, CH3CH2), 7.64 (d, J = 8.4
Hz, 2H, Ar-H), 7.91 (d, J = 8.4 Hz, 2H, Ar-H), 8.10
(d, J = 8.4 Hz, 1H, Ar-H), 8.23 (s, 1H, Ar-H), 8.45
(d, J = 8.4 Hz, 1H, Ar-H) and 8.64 ppm (s, 1H, pyridine
H4); 13C-NMR (DMSO-d6): δ = 14.34 (CH3), 26.75 (CH3),
62.67 (CH2), 113.56, 124.98, 127.68, 128.44, 128.73,
129.79, 132.93, 133.57, 133.76, 134.51, 136.14, 141.32,
144.73, 147.51, 148.43, 152.96, 158.34, 163.37 and 172.37
ppm (Ar-C and CO); MS (EI): m/z (%) 543 (M+, 8.55), 544
(M++1, 2.95). Anal. calcd. for C24H19Cl2N5O6 (544.35): C,
52.96; H, 3.52; N, 12.87. Found: C, 53.02; H, 3.45; N,
12.94.General procedure for the preparation of amidines 13a-b
Independent mixtures of the 2-amino-5-arylazonicotinates
8d,f (5 mmol), N,N-dimethylformamide dimethylacetal
(DMF-DMA) (0.6 mL, 5 mmol) in dry toluene (20 mL)
were stirred at reflux for 4 h. The separated solid product
obtained on standing at room temperature was collected
by filtration, washed by EtOH and recrystallized from
dioxane to afford the corresponding amidines 13a,b as
pure products.5-(3-Bromophenylazo)-6-(4-chlorophenyl)-2-(dimethyl-
aminomethyleneamino)nicotinic acid ethyl ester (13a)
reddish brown crystals, yield: (72%), m.p. 226.-227°C; IR
(KBr): ν/cm−1 1727 (CO ester); 1H-NMR (DMSO-d6): δ =
1.33 (t, 3H, J = 7.2 Hz, CH3CH2), 3.10 (s, 3H, CH3), 3.21
(s, 3H, CH3), 4.34 (q, 2H, J = 7.2 Hz, CH3CH2), 7.56-770
(m, 4H, Ar-H), 7.77-7.88 (m, 4H, Ar-H), 8.21 (s, 1H,
amidine H) and 8.75 ppm (s, 1H, pyridine H4); MS (EI):
m/z (%) 514 (M+, 100), 515 (M++1, 42.57). Anal. calcd. for
C23H21BrClN5O2 (514.81): C, 53.66; H, 4.11; N, 13.60.
Found: C, 53.74; H, 4.15; N, 13.53.
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(dimethylaminomethyleneamino)nicotinic acid ethyl ester
(13b)
red crystals, yield: (79%), m.p. 196–197°C; IR (KBr): ν/cm−1
1745 (CO ester); 1H-NMR (DMSO-d6): δ = 1.33 (t, 3H, J =
7.2 Hz, CH3CH2), 3.12 (s, 3H, CH3), 3.23 (s, 3H, CH3), 4.33
(q, 2H, J = 7.2 Hz, CH3CH2), 7.57 (d, J = 8.8 Hz, 2H, Ar-H),
7.91 (d, J = 8.8 Hz, 2H, Ar-H), 7.99 (d, J = 8.4 Hz, 1H,
Ar-H), 8.16 (s, 1H, Ar-H), 8.23 (s, 1H, amidine H), 8.30
(d, J = 8.4 Hz, 1H, Ar-H) and 8.82 ppm (s, 1H, pyridine
H4); ); 13C-NMR (DMSO-d6): δ = 14.52 (CH3CH2), 35.29
(CH3), 40.84 (CH3), 61.23 (CH3CH2), 113.22, 122.14,
125.54, 125.92, 128.08, 132.50, 133.30, 134.95, 136.80,
139.98, 140.08, 147.72, 149.14, 157.25, 158.55, 162.17
and 166.99 ppm (Ar-C and CO); MS (EI): m/z (%) 514
(M+, 100), 515 (M++1, 68.14). Anal. calcd. for
C23H20Cl2N6O4 (515.36): C, 53.60; H, 3.91; N, 16.31.
Found: C, 53.57; H, 3.87; N, 16.24.
General Procedure for the Preparation of pyrido[2,3-d]
pyrimidin-4-one 15a-b
Independent solutions of the amidines 13a,b (5 mmol)
in AcOH (20 mL) containing ammonium acetate (1.5 g)
were stirred at reflux for 4 h. Then, the reaction mix-
tures were cooled to room temperature and poured onto
ice cold water. The crude products were collected by fil-
tration, washed with water and recrystallized from the




Reddish brown crystals, yield: (70%), m.p. 290–291°C;
IR (KBr): ν /cm−1 3201 (NH), 1707 (CO); 1H-NMR
(DMSO-d6): δ = 7.57-7.64 (m, 3H, Ar-H), 7.79-7.88 (m,
4H, Ar-H), 7.95 (s, 1H, Ar-H), 8.46 (s, 1H, pyrimidine
H2), 8.63 (s, 1H, pyridine H5) and 12.78 ppm (s, 1H,
NH) ; 13C-NMR (DMSO-d6): δ = 117.54, 122.58, 122.74,
123.05, 125.18, 127.98, 131.67, 133.01, 134.59, 134.99,
135.56, 143.13, 150.50, 153.10, 159.76, 160.48 and 161.66
ppm (Ar-C and CO); MS (EI): m/z (%) 440 (M+, 100), 441
(M++1, 36.87). Anal. calcd. for C19H11BrClN5O (440.69):




Reddish brown crystals, yield: (74%), m.p. above 300°C;
IR (KBr): ν /cm−1 3212 (NH), 1702 ( CO); 1H-NMR
(DMSO-d6): δ = 7.62 (d, J = 8.4 Hz, 2H, Ar-H), 7.87 (d,
J = 8.4 Hz, 2H, Ar-H), 8.04 (d, J = 8.8 Hz, 1H, Ar-H),
8.16 (s, 1H, Ar-H), 8.37 (d, J = 8.8 Hz, 1H, Ar-H), 8.46
(s, 1H, pyrimidine H2), 8.66 (s, 1H, pyridine H5) and
12.74 ppm (s, 1H, NH); 13C-NMR (DMSO-d6): δ =112.84, 117.23, 123.10, 126.31, 127.88, 132.31, 133.12,
134.84, 135.78, 135.93, 140.48, 142.44, 146.98, 148.06,
154.98, 158.82 and 160.94 ppm (Ar-C and CO); MS
(EI): m/z (%) 440 (M+, 100), 441 (M++1, 55.15). Anal.
calcd. for C19H10Cl2N6O3 (441.24): C, 51.72; H, 2.28;
N, 19.05. Found: C, 51.68; H, 2.34; N, 19.13.
6-(2-Chloro-5-nitrophenylazo)-7-(4-chlorophenyl)2-thioxo-
2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one (16)
A mixture of compound 8f (1.15 g, 2.5 mmol), thiourea
(0.2 g, 2.5 mmol), and a few drops from DMF was fused
together in an oil bath under nitrogen gas at 250°C for
15 min, the fused mass was dissolved in DMF and
poured onto ice cold water, the solid obtained was
recrystallized from dioxane/DMF (2:1) to give compounds
16 as brown crystals, yield: (64%), m.p. above 300°C; IR
(KBr): ν /cm−1 3326, 3264 (2NH), 1701 (CO); 1H-NMR
(DMSO-d6): δ = 7.57 (d, J = 8.4 Hz, 2H, Ar-H), 7.85 (d, J =
8.4 Hz, 2H, Ar-H), 8.13 (d, J = 8.4 Hz, 1H, Ar-H), 8.24
(s, 1H, Ar-H), 8.41 (d, J = 8.4 Hz, 1H, Ar-H), 8.59 (s, 1H,
pyridine H5), 9.17 (s, 1H, NH), and 12.45 ppm (s, 1H,
NH); MS (EI): m/z (%) 472 (M+, 58.56), 473 (M++1,
16.77). Anal. calcd. for C19H10Cl2N6O3S (473.30):
C, 48.22; H, 2.13 N, 17.76; S, 6.77. Found: C, 48.10; H,
2.17; N, 17.65; S, 6.62.
Antimicrobial evaluation
Methodology
The antimicrobial activities of newly synthesized 22
different chemical compounds were tested using the
Agar-well diffusion technique (Isaacson and Kirchbaum)
[37] against five different microbial cultures. Pure
cultures of E. coli (Culture #0680P, Microbiologics, St.
Cloud, MN, USA) and P. aeruginosa (Culture #0416P,
Microbiologics) (Gram-negative bacteria), B. subtilis
(Culture #0269P, Microbiologics), and S. aureus (Culture
#0831P, Microbiologics) (Gram-positive bacteria) and
C. albicans (yeast) (Culture #155965, Carolina Biological
Supply, Burlington, NC, USA) were involved in the test.
Bacterial strain cultures were cultivated in Mueller–
Hinton broth (Difco) for all the bacterial strains after 24
h of incubation at 37°C. The yeasts were propagated in
Sabouraud dextrose broth (Difco) after incubation for 24
h at 25°C, [38,39] an aliquot of 0.1 ml of each bacterial
strain was inoculated and spread on nutrient agar (NA),
while 0.1 ml of the yeast was spread on potato dextrose
agar (PDA). The inoculated plates were supplied with
100 μl of each of the tested chemicals with a total final
concentration of 1 mg ml-1. The chemicals were in-
cluded in 4-mm wells produced by a sterile cork borer.
The NA plates were incubated at 37°C for 24 h while
PDA plates were incubated at 25°C for 48 h. The zones
of inhibition around the wells were determined and the
average based on three replicas was recorded. Ampicillin
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used as references in the experiment where ampicillin
was used as an antibacterial drug, which is known to
inhibit prokaryotes organisms while cycloheximide was
used as an antifungal drug, which is known to inhibit
eukaryotic organisms. The MIC measurement was deter-
mined for compounds with inhibition zones >12 mm
using a two-fold serial dilution technique [40]. The
inhibition zone diameters values cited in Table 4 are at-
tributed to the tested original concentration (1 mg/mL)
as a preliminary test and the MIC (μg/mL) values are
recorded in Table 5.
MIC measurement
The microdilution susceptibility test in Müllere-Hinton
Broth (Difco) and Sabouraud dextrose broth (Difco) at
pH 7.4 was used for the determination of the antibacter-
ial and antifungal activities, respectively [38,39,41]. Stock
solutions of the tested compounds, ampicillin and cyclo-
heximide, were prepared in DMSO at a concentration of
1000 μg/mL. Each stock solution was diluted to prepare
serial two-fold dilutions at concentrations in the range
of 500–3.125 μg/mL. The microorganism suspensions at
approximately 105 CFU/mL concentrations were inocu-
lated to the corresponding 96-well plates. The sealed
microplates were incubated at 37°C for 24 h for antibac-
terial activity and at 25°C for 48 h for antifungal activity
in a humid chamber. At the end of the incubation
period, the MIC values were recorded as the lowest con-
centrations of the substance that will inhibit the visible
growth of the microorganisms (had no visible turbidity).
Control experiments with DMSO and uninoculated
media were run parallel to the tested compounds under
the same conditions.
Conclusions
In this study, a general rule for the synthesis of 2-amino-5-
arylazo-6-aryl substituted nicotinic acids and pyridazinones
was established using 3-oxo-2-arylhydrazonopropanals
as precursors. Moreover, a novel route to pyrido[2,3-d]
pyrimidine was achieved. The antimicrobial activities of the
resulting novel 2-amino-5-arylazonicotinates, pyridazinone,
and pyrido[2,3-d]pyrimidine derivatives were investigated
with the hope of discovering new structure leads that could
serve as antibacterial and antifungal agents. The results of
the antimicrobial activities revealed that most of these
compounds were found to exhibit strong inhibitory effects
on the growth of the Gram-positive bacteria especially
B. subtilis. Compounds 1a, 8a-g, 10a-c, 15b, and 16
showed considerable antimicrobial activity against B.
subtilis (Gram-positive bacteria). The results of biological
evaluations demonstrated that most of these compounds
had promising antimicrobial activities against Gram-
positive bacteria.Additional files
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